Compare VANI & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VANI | PCF |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.0M | 98.6M |
| IPO Year | 2014 | 1994 |
| Metric | VANI | PCF |
|---|---|---|
| Price | $1.16 | $5.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.83 | N/A |
| AVG Volume (30 Days) | ★ 153.0K | 130.0K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $4.95 |
| 52 Week High | $1.92 | $6.31 |
| Indicator | VANI | PCF |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 37.88 |
| Support Level | $1.15 | $4.95 |
| Resistance Level | $1.25 | $5.63 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 4.32 | 50.00 |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.